Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Authors
Abstract
Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.
Description
Acknowledgements: We thank members of the Chavez lab for helpful discussions and insights regarding the project. Aaron Gitler provided initial insight and a number of yeast disease models, for which we are immensely grateful. We thank the ALS Stem Cell Core Program at Columbia University Irving Medical Center and its members, Hynek Wichterle, Jon Costa, Emily Lowry, and Niraj Ramsamooj for helpful discussions regarding cell-based assays and for valuable reagents. Matt Harms provided helpful discussion regarding DNAJB6 patient mutations and insight into interpretation of DMS results. Edwin Chan provided the SoxN plasmids. Richard Gardner provided the PAB1 poly-alanine plasmids. Priya Banerjee provided insight into the phase separation properties of DNAJB6 and FUS. Divyansh Argawal provided helpful discussions regarding statistical analysis of the screening platform. Debbie Hong and Sho Iketani provided valuable guidance on how to perform our deep mutational scanning studies. A.C. is supported by a Career Awards for Medical Scientists from the Burroughs Wellcome Fund and a Therapeutic Idea Award (#AL190073) from the DoD, and a fellowship award to the laboratory from Project ALS. S.J.R is supported by NIH grant F31NS111851. J.W. is supported by NSF grant 2113646. N.Z. is supported by NIH grant 2R01HG006137-10. Mouse work was supported by the National Institute of Neurological Disorders and Stroke by NIH grant 5R01NS106236 to N.A.S. This work was supported by grants from Canadian Institutes of Health Research (406915 Foundation Grant and Canadian Consortium on Neurodegeneration in Aging Grant), Wellcome Trust Collaborative Award 203249/Z/16/Z, US Alzheimer Society Zenith Grant ZEN-18-529769, Alzheimer Society of Ontario Chair in Alzheimer’s Disease Research (PStGH); Cambridge Trust and Wolfson College (C.W.C); Wellcome Trust (065807/Z/01/Z) (203249/Z/16/Z), the UK Medical Research Council (MRC) (MR/K02292X/1), and Michael J Fox Foundation (16238 and 022159)(G.S.K.S.); the European Research Council (#804581) and Alzheimer’s Society (#AS-PhD-19a-016) (J.A.V. and P.E.), Wellcome Trust (203249/Z/16/Z) and UKRI (10061100 and 10059436) (M.V.); the Dutch Ministry of Education—Sector Plan Beta for science and technology (FSR), ERC grant DiProPhys (agreement ID 10100161, T.P.J.K.); Global Research Technologies Novo Nordisk A/S (H.A., T.P.J.K.); the European Research Council under the European Union’s Seventh Framework Program (FP7/2007-2013) through the ERC grants PhysProt (agreement no. 337969; T.P.J.K.). This work was supported by a multiyear ALS Association award (21-IIA-571) to A.S.B. This study used the resources of the Herbert Irving Comprehensive Cancer Center Confocal and Specialized Microscopy Shared Resource, funded in part through NIH/NCI Cancer Center Support Grant P30CA013696. We are grateful to Dr. Barbara Corneo and Dario Sirabella for motor neuron differentiation.
Funder: Project ALS
Funder: Cambridge Trust and Wolfson College
Funder: Global Research Technologies – Novo Nordisk A/S
Funder: Dutch Ministry of Education – Sector Plan Beta
Funder: Alzheimer Society of Ontario – Chair in Alzheimer’s Disease Research
Journal Title
Conference Name
Journal ISSN
2041-1723
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Medical Research Council (MR/K02292X/1)
Wellcome Trust (203249/Z/16/Z)

